Thromboembolic events reported in association with idarucizumab and andexanet alfa: disproportionality analysis of the Food and Drugs Administration Adverse Eventr Resporting System (FAERS) database (Idarucizumab/andexanet alfa & thromboembolism)

24/10/2023
02/04/2024
EU PAS number:
EUPAS107330
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Idarucizumab_andexanet alfa_thromboebolic events_FAERS_v01_ENCEPP

English (937.54 KB - PDF) View document
Updated protocol

Idarucizumab_andexanet alfa_thromboebolic events_FAERS_v01_1_ENCEPP

First published: 22/02/2024
English (940.16 KB - PDF) View document
Study results
Study report
Other information